Arcutis Biotherapeutics, Inc.ARQTNASDAQ
Loading
R&D Expenses Over TimeStable
Percentile Rank50
3Y CAGR-25.0%
5Y CAGR-7.7%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-25.0%/yr
vs +78.6%/yr prior
5Y CAGR
-7.7%/yr
Recent deceleration
Acceleration
-103.5pp
Decelerating
Percentile
P50
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 yr
Consecutive growthStable
PeriodValueYoY Change
2025$77.05M+0.8%
2024$76.42M-30.9%
2023$110.58M-39.4%
2022$182.44M+25.3%
2021$145.56M+26.2%
2020$115.31M+215.7%
2019$36.52M+103.6%
2018$17.94M+425.9%
2017$3.41M-